Chad Morgan

Baudax Bio is a revenue-generating, specialty pharmaceutical company focused on developing and commercializing innovative products for acute care settings. The Company has multiple non-opioid therapeutics in clinical development for the treatment of pain conditions and is currently promoting their lead product, ANJESO™, indicated for use in adults for the management of moderate-to-severe pain, alone or in combination with non-NSAID analgesics. Our pipeline also includes other early-stage product candidates, including two novel neuromuscular blocker agents (NMBs) and a related proprietary chemical reversal agent, and Dex-IN, a proprietary intranasal formulation of dexmedetomidine, a selective alpha-2 adrenergic agonist that has demonstrated sedative, analgesic and anxiolytic properties. We believe we can create value for patients and shareholders through our robust pipeline of product candidates. In addition, we continue to evaluate acquisition and licensing opportunities which align with our core acute care focus.